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Asthma and lower airway disease
Safety of live attenuated influenza vaccine
(LAIV) in children with moderate to severe
asthma
Paul J. Turner, FRACP, PhD,a,b Louise Fleming, MD,a Sejal Saglani, MD,a Jo Southern, PhD,b
Nick J. Andrews, PhD,b and Elizabeth Miller, FRCPath,b on behalf of the SNIFFLE-4 Study Investigators London, United
Kingdom
Background: Live attenuated influenza vaccine (LAIV) is
recommended for annual influenza vaccination in children from
age 2 years. However, some guidelines recommend against its
use in children with asthma or recurrent wheeze due to
concerns over its potential to induce wheezing.
Objective: We sought to assess the safety of LAIV in children
with moderate to severe asthma, and in preschool children with
recurrent wheeze.
Methods: Prospective, multicenter, open-label, phase IV
intervention study in 14 specialist UK clinics. LAIV was
administered under medical supervision, with follow-up of
asthma symptoms 72 hours and 4 weeks late, using validated
questionnaires.
Results: A total of 478 young people (median, 9.3; range, 2-18
years) with physician-diagnosed asthma or recurrent wheeze
were recruited, including 208 (44%) prescribed high-dose
inhaled corticosteroids and 122 (31%) with severe asthma.
There was no significant change in asthma symptoms in the 4
weeks after administration (median change, 0; P 5 .26,
McNemar test), with no impact of level of baseline asthma
control/symptoms in predicting either a worsening of asthma or
exacerbation after LAIV using a regression model. A total of 47
subjects (14.7%; 95% CI, 11%-19.1%) reported a severe
asthma exacerbation in the 4 weeks after immunization,
requiring a short course of systemic corticosteroids; in 4 cases,
this occurred within 72 hours of vaccination. No association
with asthma severity, baseline lung function, or asthma control
was identified.
Conclusions: LAIV appears to be well tolerated in the vast
majority of children with asthma or recurrent wheeze, including
those whose asthma is categorized as severe or poorly
controlled. (J Allergy Clin Immunol 2020;145:1157-64.)
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Annual influenza vaccination for children older than 6 months
has been recommended by the Centers for Disease Control and
Prevention and its Advisory Committee on Immunization Prac-
tices since 2010.1 Children are the main spreaders of influenza
infection; vaccinating this age group is considered to be the
most effectivemethod for interrupting transmission and achieving
disease control.2 The Advisory Committee on Immunization
Practices highlights a number of groups at a higher risk for severe
complications from influenza, including children aged 6 through
59 months, and adults and children with chronic pulmonary
disease (including asthma).3 One option for immunization is the
live attenuated influenza vaccine (LAIV), an intranasally
administered vaccine that is popular among both parents and
health care professionals due to the noninvasive route of
administration.
Annual influenza vaccination of all children was introduced
into the National Immunization schedule in the United Kingdom
in 2013. The program uses LAIVand in a staged implementation
is currently targeting all children from age 2 to 11 years, as well as
children considered to be at a higher risk of influenza infection
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ACQ: Asthma Control Questionnaire
ACT: Asthma Control Test
AE: Adverse event
(c)ACT: (Children’s) Asthma Control Test
ICS: Inhaled corticosteroid
IIV: Injected influenza vaccine
LAIV: Live attenuated influenza vaccine
TRACK: Test for Respiratory and Asthma Control for Kids
(including those with asthma and recurrent wheeze).4 Surveil-
lance data have demonstrated the effectiveness of the program,5
and the safety of LAIV in the general population has been demon-
strated in a number of published studies.6
However, the Advisory Committee on Immunization Practices
recommends against LAIV in preschool children with history of
at least 1 wheezing episode in the past 12 months, and for the
vaccine to be used with caution in older children (>_5 years) with
asthma,3 due to limited evidence from 2 clinical trials that LAIV
may induce wheezing in younger children.7,8 These concerns
have not been reproduced in other studies9-12 nor through post-
marketing surveillance.13-17
In the UK setting, where up to 9% of children have a diagnosis
of asthma,18 the SNIFFLE-2 study provided evidence for the
safety of LAIV in children with mild to moderate asthma. How-
ever, there are insufficient data in children requiring higher doses
of inhaled corticosteroids (ICSs) or with ‘‘difficult’’ asthma to
make any recommendations in these cohorts.19 Elsewhere, there
has been significant heterogeneity in defining poorly controlled
or ‘‘difficult’’ asthma in postmarketing surveillance.16,17 We
therefore sought to assess the safety of LAIV in children with
moderate to severe asthma in a multicenter, prospective interven-
tional study.
METHODS
This was a phase IVopen-label study of LAIV in young people with asthma
during the 2016/2017 influenza season across 14 specialist pediatric asthma
clinics in the United Kingdom. Eligible participants were aged 2 to 18 years,
with a current physician diagnosis of asthma and prescribed regular ICS.
Preschool-age children (between 2 and 5 years) were also eligible if they had
experienced 2 or more exacerbations of wheezing in the previous year requiring
oral steroids or hospitalization. A number of different (but established)
definitions were used to assign severity, to reflect differences in national and
international practice (outlined in Table I20-22). Children requiring oral steroids
or receiving biologics such as omalizumabwere not excluded. Participants were
excluded if they had previously required invasive ventilation because of a respi-
ratory illness in the preceding 2 years or had a contraindication to LAIV (egg
allergy notwithstanding). Vaccination was deferred for acute febrile illness.
We did not exclude children with acutewheeze, unless occurring within the pre-
vious 72 hours in the context of a new acute exacerbation.
The study was approved by theWest Midlands-Edgbaston Research Ethics
Committee (16/WM/0276), and the parent/guardian of each participant gave
written informed consent. Children older than 8 years were encouraged to
provide assent. The study sponsor was Imperial College Healthcare NHS
Trust. This study was registered with ClinicalTrials.gov (NCT02866942) and
the EU Clinical Trials Register, EudraCT (2016-002352-24).
Procedures
Participants underwent clinical evaluation (including vital signs and lung
function [FEV1 and/or peak expiratory flow rate] where age-appropriate).
They (or their parents) were also asked to complete the following age-
appropriate validated questionnaires to assess asthma control:
d Age 2 to 4 years: Test for Respiratory and Asthma Control for Kids
(TRACK)23
d Age 5 to 11 years: Asthma Control Questionnaire (ACQ)24 and Chil-
dren’s Asthma Control Test ((c)ACT),25 which assess asthma symp-
toms/control over the preceding 1 and 4 weeks, respectively;
d Age 121 years: ACQ and Asthma Control Test (ACT).
Subjects were then administered quadrivalent LAIV (Fluenz-Tetra, produced
for the 2016/2017 influenza season) following the method specified on the
approved summary of product characteristics. Parents were telephoned at least
72 hours after vaccination to document any adverse events (AEs), and then
contacted by either email or telephone 4 weeks later to reassess ACT score and
associated symptoms. Vaccine-naive subjects younger than 9 years were offered
a second dose of LAIV 4 weeks later, in line with national guidelines.
Outcomes
The primary outcome was the change in asthma control before and in the 4
weeks after LAIV in young people with asthma/recurrent wheezing, as assessed
by age-appropriate questionnaire (TRACK or (c)ACT), and by severity
classification. Clinical secondary outcomes were incidence of AEs including
severe asthma exacerbation and seriousAEs (sAEs) in the 4weeks after LAIVin
study participants. We used the American Thoracic Society/European Respi-
ratory Society definition for a severe asthma exacerbation, namely, (1) use of
systemic corticosteroids or an increase from a stable maintenance dose, for at
least 3 days; OR (2) unscheduled visit to an emergency department or hospital
admission because of asthma, requiring systemic corticosteroids.26AEswere re-
viewed by an independent data monitoring committee, and causality assigned in
conjunction with local study teams.
Statistical analyses
Analyses were planned prospectively and detailed in a statistical analysis
plan. For the primary outcome, the change in TRACK or (c)ACT score pre-
and 4 weeks post-LAIV was assessed by McNemar test for paired data. The
minimum important difference for the (c)ACT score is around 2 points in
younger children25 and 3 points in adults,27 and 10 points for TRACK.23 For
the purpose of this analysis, a change in (c)ACTof at least 3 points or 10 points
for TRACK was determined to be a clinically relevant change, where this re-
sulted in a change in symptom control from reasonable ((c)ACT score >_20 or
TRACK score >_80 points) to suboptimal control ((c)ACT score <20 or
TRACK score <80 points). Severity was defined as outlined in Table I, and
a further definition was included as an additional post hoc analysis to reflect
the new definition for difficult asthma adopted by the British Thoracic Society
in 2016 and included in the 2019 guideline.21 Subgroup analyses were per-
formed according to asthma severity, previous vaccination status, and by
age group (2-4, 5-11, 121 years). For secondary outcomes, the incidence of
reactions (immediate and delayed) and significant asthma exacerbation after
LAIVwere estimatedwith 2-sided exact 95%CIs.We also developed a regres-
sion model to assess for baseline characteristics associated with the occur-
rence of significant exacerbation. The analysis data set was as treated and
with the relevant safety data measured.
Sample size was determined on the primary objective. A total of 720
children (split 50:50 into higher/regular dose of ICS)would give 80% power at
a 5% significance level to detect an improvement in 10% versus deterioration
in 17.5% as significant. Increasing sample size to 840 would allow for
approximately 15% attrition. In reality, recruitment was lower than planned
and attrition greater, such that the study was powered to detect only larger
differences (eg, with n 5 300, 10% vs 22.5%).
RESULTS
A total of 479 children were recruited and received at least 1
dose of LAIV. One child was excluded because of improper
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consent, leaving an analysis cohort of 478 participants. The
median age of the cohort was 9.3 years (range, 2-18 years) and
288 (60%) were males. A total of 332 (69%) had received
influenza vaccination previously, of whom 222 had been given
LAIV. All participants had physician-diagnosed asthma or
recurrent wheeze (Table I). Coexisting atopic diseases were com-
mon: 63% had allergic rhinitis, 48% eczema, and 44% food al-
lergy. A second LAIV dose was administered to 34 children
because of no previous vaccination; a further 38 were eligible
for a second dose, but did not receive it because of expiry of the
vaccine (8 children) or the family declining a second visit (30
children), as shown in the CONSORT diagram (Fig 1).
Primary outcome: Change in asthma control after
LAIV
Follow-up data for asthma control were available for 319 of
478 (67%) participants: 71%, 67%, and 65% aged 2 to 4, 5 to 11,
and 121 years, respectively. Therewere no obvious differences in
age, baseline asthma control, and previous vaccination status
between those in whom follow-up data were available and those
without (see Table E1 in this article’s Online Repository at www.
jacionline.org). We did observe fewer responses in teenagers
receiving high-dose ICSs, but not in the preschool or 5- to 11-
year age group. The change in (c)ACT score for the 4 weeks after
LAIVadministration in subjects older than 5 years is shown in Fig
2. There was no significant change in (c)ACT score for children 5
years and older (median change, 0; P5.18, McNemar test), with
58 (22%) subjects reporting an improvement in asthma control at
least equal to the minimum important difference and 70 (27%) re-
porting a deterioration. Therewas no significant change in asthma
control by age of child (5-11 and 121 years; P 5 .71 and .08,
respectively). Analyzing the data according to severity of asthma,
we did not identify any particular severity definition associated
with a significant change in asthma control (Table II; see Table
E2 in this article’s Online Repository at www.jacionline.org),
although subjects aged 121 years without ‘‘difficult asthma’’
paradoxically reported a mild worsening in ACT (although this
analysis might have been affected by regression to themean). Pre-
vious vaccination status did not affect change in asthma control
(P 5 .36).
Children younger than 5 years were initially analyzed sepa-
rately, because of the use of a different tool (TRACK) to evaluate
any potential change in respiratory symptoms. There was no
significant change in TRACK score after LAIVoverall (Fig 3,P5
.54, McNemar test), nor by severity subgroup.
Combining all age groups, Table II reports the number of pa-
tients with a significant change in symptom control across all











Sex: male 52 (61) 151 (64) 85 (54) 288 (60)
Baseline lung function
FEV1 (% predicted), median (IQR) NA 91 (78-102) 92 (80-99) NA
(n 5 138) (n 5 122)
PEFR (% predicted), median (IQR) NA 87 (75-101) 91 (85-100) NA
(n 5 58) (n 5 48)
Baseline asthma control score, median (IQR)
TRACK 55 (35-65) NA NA NA
(c)ACT NA 19 (15-22) 19 (16-22)
ACQ NA 6 (2-12) 6 (3-11)
Previous influenza vaccination 41 (48) 186 (79) 120 (76) 332 (69)
Previous LAIV 24 (28) 134 (57) 64 (41) 222 (46)
Asthma severity
‘‘Persistent poor control’’20:
Age 2-4 y: ICS >200 mg 1 LTRA or >_2 exacerbations in past year
requiring oral steroids/hospitalization
68 (80) 88 (37) 73 (46) 229 (48)
Age 5-11 y: ICS >_ 400 mg/d
Age 121y: ICS >_ 800 mg/d
High-dose ICSs, n (%)
Age 2-4 y: ICS >_ 400 mg/d 48 (57) 63 (27) 97 (61) 208 (44)
Age 51 y: ICS >_ 800 mg/d
Severe asthma (according to ATS/ERS guidelines)22
High-dose ICS AND at least 1 of: NA 51 (22) 71 (45) 122 (31*)
ACT score <20
>_2 courses of systemic steroids in the past year
Serious exacerbation (hospital admission in last year)
FEV1 <80%
‘‘Difficult asthma’’: persistence of symptoms despite treatment with
high-dose therapies21
54 (64) 46 (20) 42 (27) 142 (30)
ATS, American Thoracic Society; ERS, European Respiratory Society; IQR, interquartile range; LTRA, leukotriene receptor antagonist; NA, not applicable/available; PEFR, peak
expiratory flow rate.
Values are n (%) unless otherwise indicated.
*Excluding study participants <5 years.
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ages for the analysis of primary outcome, and by severity classi-
fication. Overall, the proportion of subjects with a significant
deterioration after LAIV (37 of 319 [11.6%]; 95% CI, 8.3%-
15.6%) was similar to the proportion of subjects reporting
improved control (28 of 319 [8.8%]; P 5 .26); thus, these data
do not provide evidence that any deterioration in symptom control
was due to receipt of LAIV.
AEs after immunization
Nine AEs were reported (in 9 individuals) within 2 hours of
vaccination (see Table E3 in this article’s Online Repository at
www.jacionline.org). Six were not consistent with a potential
IgE-mediated allergic response (as defined by international
consensus criteria) thought to be related to vaccine. Thus, the
rate of acute AEs after immunization was 3 of 478 or 0.63%
(95% CI, 0.13%-1.82%), which is in line with the reported rate
of AEs described in the literature for the normal population.7
Follow-up to 72 hours was completed for 440 (92%) partici-
pants. Two hundred five delayed AEs were reported by parents in
150 children. After excluding 11 AEs that were deemed unlikely
to have been vaccine-related, a total of 139 children experienced
delayed events (occurring between 2 and 72 hours after vaccine
administration), described in Table III. Twenty-eight of 440 chil-
dren (6.4%; 95% CI for population, 4.3%-9.1%) experienced
parent-reported wheezing within 72 hours, of whom 4 were pre-
scribed a short course of systemic corticosteroids. More delayed
AEs were reported in the younger ages (which may reflect an
increased rate of viral infections in this age group), but otherwise
the occurrence of delayedAEswas not associated with any partic-
ular baseline characteristic, including baseline ACT/ACQ score
or lung function (see Table E4 in this article’s Online Repository
at www.jacionline.org).
Asthma exacerbation after 72 hours and SAEs
There were 4 SAEs during the study, 2 of which were
considered potentially attributable to LAIV (details are provided
in Table E5 in this article’s Online Repository at www.jacionline.
org). In total, 47 of 319 subjects (9 of 60 children aged 2-4 years,
FIG 1. Participant flow diagram. Thirteen children had consent but were not eligible for the study: 6 due to
recent antihistamine use (family declined a further study appointment); 5 refused after parental consent had
been obtained; 2 with unstable asthma (and who were given IIV instead).
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and 22 of 157 and 16 of 102 subjects aged 5-11 and 121 years,
respectively) reported a severe asthma exacerbation in the 4
weeks after immunization, giving a rate of 14.7% (95% CI,
11.0-19.1). We developed a logistic regression model to try and
predict the risk of exacerbation on the basis of asthma control
and lung function before LAIV, for each age group. No associa-
tion between baseline asthma control and odds of exacerbation
was identified for the 2- to 4-year and the 5- to 11-year age groups
(P5.69 and .65, respectively). For subjects aged 121 years, there
was no association with baseline lung function or ACQ score after
adjusting for ACT score (P5 .17 and .66, respectively). Baseline
ACT score was more strongly associated with exacerbation, with
an odds ratio of 0.29 per 5 points (95% CI, 0.14-0.59; P5 .001);
however, the area-under-receiver-operating-characteristic curve
was 0.796, which implies that the model was not highly
predictive.
DISCUSSION
We did not find any evidence that administration of LAIV in
young people with severe or ‘‘difficult’’ asthma resulted in an
adverse safety signal, including in preschool-age children with
FIG 2. Change in ACT score at 4 weeks post-LAIV, compared with baseline, in children older than 5 years
with a history of asthma.
TABLE II. Change in symptom control >_minimum important difference for study population (and by severity definition) where this
resulted in a change in symptom control from well controlled to suboptimal (or vice versa)




All ages 319 28 (9) 254 (80) 37 (12) .26
2-4 y 60 3 (5) 49 (82) 8 (13) .13
51 y 259 25 (10) 205 (79) 29 (11) .59
‘‘Persistent poor control’’
All ages 147 12 (8) 118 (80) 17 (12) .35
2-4 y 45 3 (7) 37 (82) 5 (11) .48
51 y 102 9 (9) 81 (79) 12 (12) .51
High-dose ICS
All ages 127 8 (6) 106 (83) 13 (10) .26
2-4 y 33 2 (6) 29 (88) 2 (6) 1.00
51 y 94 6 (6) 77 (82) 11 (12) .23
‘‘Difficult asthma’’
All ages 90 7 (8) 79 (88) 4 (4) .37*
2-4 y 37 3 (8) 30 (81) 4 (11) .71
51 y 53 4 (8) 49 (92) 0 (0) .05*
Values are n (%).
*This severity definition is partially dependent on the (c)ACT score, so this P value may be influenced by regression to the mean.
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severe wheezing. Although 15% of participants reported an
asthma exacerbation in the 4 weeks after LAIV, this was not
associated with asthma severity or baseline asthma control/lung
function. This study therefore provides reassuring evidence to
justify the use of LAIV in children with moderate to severe
asthma.
Concerns with respect to LAIV in children with wheezing were
first raised in 2 randomized, double-blind trials. Bergen et al8 re-
ported a significantly increased relative risk (4.06; 90% CI, 1.29-
17.86) for wheezing in the 42 days after vaccination in children
aged 18 to 35 months with a history of ‘‘asthma or reactive air-
ways disease,’’ despite the study specifically excluding children
with a parent-reported history of asthma.8 In a second study,
Belshe et al7 reported an increased rate of ‘‘medically significant
wheezing’’ in infants aged 6 to 11 months receiving LAIV
compared with injected influenza vaccine (IIV) (13.6% LAIV
vs 10.4% IIV), but not in children older than 2 years (2.1%
LAIV vs 2.5% IIV).7 The authors further noted a higher (but
not significant) rate of hospitalization in children with a history
of wheezing, although the study excluded any participant with a
history of wheezing in the 42 days before LAIV.
In contrast, numerous other studies, including data from
randomized controlled trials9-12 and postmarketing population-
based studies,13-17 have found no evidence for an adverse safety
signal in young people with asthma older than 2 years (which is
the lowest age that LAIV is licensed for use in). Ambrose et al un-
dertook an analysis of 2 previously published randomized multi-
national trials,7,12 which when combined included 1940 children
aged 2 to 5 years with asthma or a history of wheezing, and found
no evidence for increased risk of wheezing after LAIV compared
with IIV, although subjects with an episode of wheeze in the 42
days before vaccination were excluded.28 In the SNIFFLE-2
study, we did not identify an adverse safety signal after LAIV
in 445 children with mild to moderate asthma.19 More recently,
an analysis of data from the Clinical Practice Research Datalink
relating to more than 11,000 young people at a ‘‘higher risk’’
for influenza disease (including patients with asthma, who consti-
tuted more than 70% of the cohort) receiving LAIV in general
practice in the United Kingdom found no evidence for increased
hospitalization after vaccination,29 although as the authors
comment, allocation to treatment (LAIV, IIV, or no vaccine)
was not controlled and therefore the results may have been
confounded by differences between treatment groups at baseline.
Many studies have used a definition of ‘‘medically significant
wheeze’’ (ie, wheeze that requires review by a health care
professional) in the 42 days postvaccination as the outcome
measure for lower respiratory tract symptoms, which is insensi-
tive because parents of children with recurrent wheezing will
often manage their child’s symptoms at homewithout recourse to
a health care professional. These studies also frequently exclude
children with wheezing up to 42 days before vaccination, and so
exclude those with significant underlying disease who are likely
to be at a greater risk of lower respiratory tract events after LAIV.
In this study, children with active wheezing in the previous 3 days
were not specifically excluded (subject to assessment by the site
lead investigator) and our strategy to specifically recruit young
people with severe or ‘‘difficult’’ asthma provide useful data on
the safety of LAIV in children with more symptomatic disease.
Strengths and limitations of study
To focus on children with more severe asthma, we specifically
targeted patients attending specialist asthma clinics in the United
Kingdom, in whom asthma treatment had been guided by
FIG 3. Change in TRACK score at 4 weeks post-LAIV, compared with baseline, in children aged 2 to 4 years
with a history of recurrent wheeze.
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specialists in severe asthma. To this extent, around 50% of
participants met international criteria for severe or difficult
asthma. Although the optimal design would have randomized
participants to receive either LAIV or IIV (with appropriate
placebo controls), we considered that this would have adversely
affected recruitment in our target population. We therefore opted
for an open, observational design rather than a placebo-
controlled, more invasive study (using IIV/placebo injection) to
maximize recruitment.
Despite this, recruitment to this study was challenging because
more than 50% of children screened for inclusion through our
severe asthma clinics had already received LAIV through the
national vaccine program. This raises an issue in terms of the
extent to which public health guidance filters through to those
administering vaccine in the community and through primary
care: under previous guidance from Public Health England,
children receiving high-dose ICSs ‘‘should only be given LAIV
on the advice of their specialist,’’ yet clearly this advice was not
always adhered to.
We did not identify any evidence to suggest that wheezing or
asthma exacerbation postvaccination was related to baseline
severity, asthma control, or lung function, nor did we find any
evidence to suggest a systematic worsening of asthma control due
to LAIV. Follow-upwas complete in only 67% of participants, but
there were no obvious differences in baseline asthma control
between those with follow-up and those without, implying that
baseline asthma control was not a confounder. We excluded
children with a history of an episode of invasive ventilation due to
a respiratory illness in the preceding 2 years, and therefore we
cannot make any recommendations for children in this category.
These data provide evidence for the safety of LAIV in children
with severe asthma, despite the above limitations with respect to
the absence of a control group receiving IIV or placebo and the
lower-than-anticipated recruitment and lack of 4-week follow-up
data in one-third of participants. To provide further reassurance,
we also interrogated our national pharma-surveillance scheme for
adverse events due to LAIV in children with asthma. Given the
widespread use of LAIVin theUKpediatric population, including
in patients with severe asthma (as evidenced by our observation
that many potential participants had already been given LAIV
when approached), we considered this might provide further
useful data. Over a 5-year period to 2018, there were 41
notifications of asthma exacerbation post-LAIV (an average of
8 per annum), although of course these could be unrelated to
LAIV. In the context of more than 3 million doses of LAIV given
annually to this age group, these figures provide additional
reassurance.
Conclusions and policy implications
This study provides evidence for the revised UK guidance for
the 2019/2020 season that ‘‘children with asthma on inhaled
corticosteroids may safely be given LAIV, irrespective of the dose
prescribed,’’ although LAIV continues to be not recommended in
those with an acute exacerbation of asthma symptoms in the
previous 72 hours.6
We thank our datamonitoring committee (Glenis Scadding [Chair], Andrew
Riordan, J€urgen Schwarze, and Andre Charlett). We also thank our co-
investigators in the SNIFFLE-4 Study team and colleagues at Public Health
England for their support in data management: Pauline Kaye, Deborah Cohen,
Rashmi Malkani, and Teresa Gibbs. Finally, we thank the many parents and
children who participated in the study.
The SNIFFLE-4 Study Investigators are as follows: Alexandra Adams
(Leeds Teaching Hospitals NHS Trust), Christine Doyle (Alder Hey
Children’s NHS Foundation Trust), Michel Erlewyn-Lajeunesse (University
Hospital Southampton NHS Foundation Trust), Katy Fidler (Brighton &
Sussex University Hospitals NHS Trust), Louise Fleming (National Heart &
Lung Institute, Imperial College London, & Royal Brompton & Harefield
NHS Foundation Trust), Atul Gupta (Kings College Hospital NHS Foundation
Trust), Stephen M. Hughes (Central Manchester University Hospitals NHS
Foundation Trust), Andrew Ives (Oxford University Hospitals NHS Founda-
tion Trust), Nicola Jay (Sheffield Children’s Hospital NHS Foundation Trust),
Sonal Kansra (Sheffield Children’s Hospital NHS Foundation Trust), Louise
Michaelis (Great North Children’s Hospital, Newcastle-upon-Tyne Hospitals
NHS Foundation Trust), Samantha Moss (Great North Children’s Hospital,
Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Clare Murray
(Central Manchester University Hospitals NHS Foundation Trust), Prasad
Nagakumar (Birmingham Children’s Hospital NHS Foundation Trust),
Graham Roberts (University Hospital Southampton NHS Foundation Trust),
Sejal Saglani (National Heart & Lung Institute, Imperial College London, &
Royal Brompton & Harefield NHS Foundation Trust), Paul Seddon (Brighton
& Sussex University Hospitals NHS Trust), Ian Sinha (Alder Hey Children’s
NHS Foundation Trust), Gary Stiefel (University Hospitals of Leicester NHS
Trust), HuwM. Thomas (University Hospitals Bristol NHS Foundation Trust),
TABLE III. Delayed AEs occurring up to 72 hours after LAIV








Upper respiratory tract (any) 55 12.5% (9.6%-16.0%)
Isolated symptoms only, <24-h
duration
23 5.2% (3.3%-7.7%)
Isolated symptoms only, >24-h
duration
31 7.1% (4.8%-9.9%)




Lower respiratory tract (any) 56 12.7% (9.8%-16.2%)
Parent-reported wheeze 28 6.4% (4.3%-9.1%)
Constitutional
Any 58 13.2% (10.2%-16.7%)
Fever <24 h 10 2.3% (1.1%-4.1%)
Fever >24 h 7 1.6% (0.6%-3.3%)




Flare in eczema 3 0.7% (0.1%-2.0%)




Vomiting, nausea, abdominal pain 9 2.1% (0.9%-3.9%)
Loose stools 2 0.5% (0.1%-1.6%)
Ear-nose-throat
Mild nose bleed 3 0.7% (0.1%-2.0%)
Sore throat 4 0.9% (0.3%-2.3%)
Ocular
Itch, redness 1 0.2% (0.01%-1.3%)
Neurological
Any 0 0% (0.0%-0.8%)
Cardiovascular
Any 0 0% (0.0%-0.8%)
J ALLERGY CLIN IMMUNOL
VOLUME 145, NUMBER 4
TURNER ET AL 1163
and Paul J. Turner (National Heart &Lung Institute, Imperial College London,
& Imperial College Healthcare NHS Trust).
Clinical implications: This study provides evidence that chil-
dren with asthma may safely be given LAIV irrespective of
the dose of ICSs prescribed, although LAIV is not recommen-
ded in those with an acute exacerbation of asthma symptoms.
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TABLE E1. Comparison between those subjects with follow-up data relating to asthma control at 4 weeks and those without
Characteristic
Subjects with follow-up
data (n 5 319)
Subjects without follow-up
data (n 5 159) P value
Age (y)
2-4 60 (19) 25 (16) .65
5-11 157 (49) 78 (49)
121 102 (32) 56 (35)
Sex: male 190 (60) 98 (62) .69
Baseline asthma control score, median (IQR)
TRACK (age 2-4 y) 50 (30-65) 60 (38-75) .20
(c)ACT (age 5-11 y) 19 (16-22) 19 (13-23) .34
ACT (age 121 y) 19 (17-22) 19 (14-22) .16
ACQ (age 51 y) 6 (2-10) 6 (2-13) .24
Receiving high-dose ICSs
Age 2-4 y: ICS >_ 400 mg/d 33 (10) 15 (9) .87
Age 5-11 y: ICS >_ 800 mg/d 40 (13) 23 (14) .57
Age 121 y: ICS >_ 800 mg/d 54 (17) 43 (27) .01
Previous influenza vaccination 225 (71) 107 (67) .53
Previous LAIV 156 (49) 66 (42) .14
IQR, Interquartile range.
Values are n (%) unless otherwise indicated.
J ALLERGY CLIN IMMUNOL
APRIL 2020
1164.e2 TURNER ET AL
TABLE E2. Change in symptom control >_minimum important difference for study population, and by severity definition




All ages 319 77 (24) 148 (46) 94 (29) .14
2-4 y 60 19 (32) 17 (28) 24 (40) .54
51 y 259 58 (22) 131 (51) 70 (27) .18
5-11 y 157 40 (25) 76 (48) 41 (26) .71
121 y 102 18 (18) 55 (54) 29 (28) .08
‘‘Persistent poor control’’
All ages 147 42 (29) 54 (37) 51 (35) .46
2-4 y 45 17 (38) 10 (22) 18 (40) .95
51 y 102 25 (25) 44 (43) 33 (32) .32
5-11 y 56 15 (27) 25 (45) 16 (29) .83
121 y 46 10 (22) 19 (41) 17 (37) .24
High-dose ICS
All ages 127 35 (28) 50 (39) 42 (33) .46
2-4 y 33 13 (39) 7 (21) 13 (39) .84
51 y 94 22 (23) 43 (46) 29 (31) .26
5-11 y 40 12 (30) 19 (48) 9 (22) .63
121 y 54 10 (19) 24 (44) 20 (37) .07
‘‘Difficult asthma’’
All ages 90 34 (38) 31 (34) 25 (28) .30*
2-4 y 37 15 (41) 9 (24) 13 (35) .58
51 y 53 19 (36) 22 (42) 12 (23) .23*
5-11 y 24 10 (42) 9 (38) 5 (21) .21*
121 y 29 9 (31) 13 (45) 7 (24) .62*
Values are n (%).
*This severity definition is partially dependent on the (c)ACT score, so this P value may be influenced by regression to the mean.
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TABLE E3. AEFI reported within 2 h of LAIV administration





1 20-60 Mild itchy facial rash; no recurrence with second dose of LAIV given 1 mo
later
Yes Unlikely
2 5-20 Mild generalized pruritus, no rash
?due to environmental exposure
Yes Possible
3 5-20 Itchy facial rash
?contact reaction from vaccine
Yes Probable
4 20-60 Rhinitis, facial hives, and mild angioedema. Possible causation due to
exposure to a food allergen
Yes Unlikely
5 5-20 Localized urticaria to nasal bridge and mild upper-lip swelling
?contact reaction from vaccine
Yes Probable
6 5-20 Nausea No
7 5-20 Itchy nose No
8 20-60 Occasional sniffing No
9 20-60 Generalized mild rash and itchy throat. No other symptoms. Frequently
develops similar symptoms due to environmental exposure
Yes Unlikely
AEFI, Adverse event following immunization.
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TABLE E4. Relationship between the occurrence of delayed events (in the 72 hours after LAIV) and baseline characteristics
Factor Level All delayed AEs P value
Lower respiratory
tract AEs only P value
Age Median, IQR 8.7 (5.0-12.3) .02 7.8 (4.2-11.9) .01
Age 2-4 y 35 of 77 (45%) 18 of 77 (23%)
Age 5-11 y 65 of 220 (30%) 24 of 220 (11%)
Age 121 y 39 of 143 (27%) 14 of 143 (10%)
Baseline (c)ACT or TRACK score Q1* 34 of 92 (37%) .12 12 of 92 (13%) .77
Q2* 33 of 97 (34%) 15 of 97 (15%)
Q3* 44 of 145 (30%) 17 of 145 (12%)
Q4* 28 of 103 (27%) 12 of 103 (12%)
Lung function (FEV1 or PEFR) >95% 30 of 106 (28%) .59 12 of 106 (11%) .97
95%-90% 12 of 38 (32%) 4 of 38 (11%)
89%-90% 14 of 55 (25%) 3 of 55 (5%)
79%-70% 9 of 36 (25%) 6 of 36 (17%)
69%-60% 7 of 20 (35%) 1 of 20 (5%)
59%-50% 4 of 10 (40%) 2 of 10 (20%)
<50% 1 of 2 (50%) 0 of 2 (0%)
Baseline ACQ score 0-4 41 of 160 (26%) .22 14 of 160 (9%) .23
5-9 28 of 94 (30%) 10 of 94 (11%)
10-14 20 of 58 (34%) 11 of 58 (19%)
15-19 6 of 30 (20%) 1 of 30 (3%)
20-24 8 of 17 (47%) 2 of 17 (12%)
25-30 1 of 3 (33%) 0 of 3 (0%)
‘‘Persistent poor control’’ No 70 of 235 (30%) .41 26 of 235 (11%) .31
Yes 69 of 205 (34%) 30 of 205 (15%)
High-dose ICS No 73 of 257 (28%) .10 28 of 257 (11%) .19
Yes 66 of 183 (36%) 28 of 183 (15%)
‘‘Difficult asthma’’ No 97 of 316 (31%) .57 35 of 316 (11%) .11
Yes 42 of 124 (34%) 21 of 124 (17%)
Atopic status
Eczema No 64 of 224 (29%) .18 31 of 224 (14%) .57
Yes 75 of 216 (35%) 25 of 216 (12%)
Allergic rhinitis No 46 of 168 (27%) .14 21 of 168 (13%) 1.0
Yes 93 of 272 (34%) 35 of 272 (13%)
IgE-mediated food allergy No 79 of 239 (33%) .54 34 of 239 (14%) .32
Yes 60 of 201 (30%) 22 of 201 (11%)
Previous influenza vaccine No 42 of 119 (35%) .42 13 of 119 (11%) .63
Yes 96 of 308 (31%) 41 of 308 (13%)
PEFR, Peak expiratory flow rate.
Four children met the criteria for severe exacerbation within 72 hours, aged 3, 4, 7, and 15 years; 3 had coexisting atopy, and 2 (aged 3 and 7 years) had previously received LAIV.
*Data analyzed in quartiles, for ACT this was <15,15-18,19-22, and >_23; for TRACK, <35, 35-50, 55-65, and >_70.
Trend test across categories.
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TABLE E5. Serious AEs reported during the study





1 Subject with severe asthma developed viral symptoms and wheeze 1 wk post-LAIV. Assessed in
hospital: oxygen saturations 94% in room air. Admitted for 3 d observation, no change in medical
management instituted
Probable Y
2 Subject with severe asthma noted to have possible early signs of chest infection noted at assessment
pre-LAIV, and oral antibiotics commenced. LAIV administered after review by local Investigator.
Three days later, subject presented to local hospital with increased wheeze and breathlessness, and
admitted for 3 d. Treated with nebulized salbutamol and intravenous antibiotics
Possible Y
3 Subject with severe asthma; 19 d after LAIV, asthma exacerbation and was admitted to hospital
overnight for hourly nebulizers, magnesium sulfate, and intravenous antibiotics. Discharged the
next day
Unlikely* Y
4 Subject has severe asthma, previous HDU admissions, tolerated LAIV in previous years. Three weeks
after LAIV, developed increasing wheeze/cough, prompting presentation to hospital on day 3 of
illness. Diagnosed with asthma exacerbation and admitted to HDU, given magnesium sulphate,
aminophylline, steroids, and nebulized salbutamol. No antibiotics started. No virology sent, blood
studies demonstrated neutrophilia with elevated CRP (48 mg/L). No focal abnormality on chest
x-ray. Discharged home after 48 h
Unlikely* Y
CRP, C-reactive protein; HDU, high dependency unit; IDMC, Independent Data Monitoring Committee; N, no; PI, principal investigator; Y, yes.
*IDMC ascribed unlikely due to very low probability of ongoing viral shedding 3 weeks after LAIV.E1
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